Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Large Decrease in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,980,000 shares, a decline of 21.4% from the February 13th total of 2,520,000 shares. Approximately 4.2% of the company’s stock are sold short. Based on an average daily volume of 5,940,000 shares, the short-interest ratio is presently 0.3 days.

Cardio Diagnostics Price Performance

CDIO stock opened at $0.45 on Monday. The company’s 50-day moving average is $0.53 and its 200-day moving average is $0.47. Cardio Diagnostics has a 1 year low of $0.19 and a 1 year high of $1.77.

Hedge Funds Weigh In On Cardio Diagnostics

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Cardio Diagnostics by 97.6% during the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after buying an additional 179,978 shares during the last quarter. Two Sigma Securities LLC purchased a new position in Cardio Diagnostics during the 4th quarter worth $48,000. Jane Street Group LLC bought a new position in shares of Cardio Diagnostics during the fourth quarter valued at about $103,000. Finally, Millennium Management LLC purchased a new position in Cardio Diagnostics during the fourth quarter worth about $236,000. 8.06% of the stock is owned by institutional investors and hedge funds.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.